← Back to Search

MEG

Noninvasive Imaging for Epilepsy

N/A
Recruiting
Led By Sara K Inati, M.D.
Research Sponsored by National Institute of Neurological Disorders and Stroke (NINDS)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients aged 8 and older
Patients who had epilepsy surgery with presurgical evaluation under a specific protocol
Timeline
Screening 3 weeks
Treatment Varies
Follow Up all outcomes in this study are exploratory.
Awards & highlights
No Placebo-Only Group

Summary

This trial will compare the sensitivities and specificities of morphometric analysis techniques using MRI images to pre- and postsurgical localization of epileptic foci in patients undergoing presurgical evaluation for medically refractory epilepsy, in order to establish an age-stratified normative imaging database.

Who is the study for?
This trial is for adults and children aged 8 or older with uncontrolled focal epilepsy, who are being evaluated for or have had epilepsy surgery. Participants must be able to consent themselves or through a guardian and cooperate with MRI scans without anesthesia.
What is being tested?
The study aims to improve the detection of epileptic foci using MRI before and after surgery in patients with refractory epilepsy. It also involves creating a database from healthy volunteers for comparison, plus additional brain imaging (MEG) and cognitive testing.
What are the potential side effects?
There are generally no direct side effects from participating in this trial as it involves noninvasive imaging techniques like MEG and MRI. However, some individuals might experience discomfort during scanning or claustrophobia.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 8 years old or older.
Select...
I had epilepsy surgery after a detailed presurgical evaluation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~all outcomes in this study are exploratory.
This trial's timeline: 3 weeks for screening, Varies for treatment, and all outcomes in this study are exploratory. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
All outcomes in this study are Exploratory.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: healthy volunteersExperimental Treatment2 Interventions
healthy volunteers
Group II: PatientsExperimental Treatment2 Interventions
Patients
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MEG
2017
N/A
~1280
MRI
2009
Completed Phase 2
~2810

Find a Location

Who is running the clinical trial?

National Institute of Neurological Disorders and Stroke (NINDS)Lead Sponsor
1,384 Previous Clinical Trials
651,988 Total Patients Enrolled
79 Trials studying Epilepsy
24,861 Patients Enrolled for Epilepsy
Sara K Inati, M.D.Principal InvestigatorNational Institute of Neurological Disorders and Stroke (NINDS)
5 Previous Clinical Trials
2,376 Total Patients Enrolled
3 Trials studying Epilepsy
2,318 Patients Enrolled for Epilepsy

Media Library

MEG (MEG) Clinical Trial Eligibility Overview. Trial Name: NCT02107989 — N/A
Epilepsy Research Study Groups: healthy volunteers, Patients
Epilepsy Clinical Trial 2023: MEG Highlights & Side Effects. Trial Name: NCT02107989 — N/A
MEG (MEG) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02107989 — N/A
~162 spots leftby Mar 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top